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Abstract 
The large nuclear protein PFAP termed as Putative Fanconi Anaemia protein is a 
novel uncharacterised protein, approximately 550 KDa in size, with few identifiable domains. 
However, till date its function remains elusive. According to unpublished results from our 
laboratory, cells lacking PFAP exhibit loss of phenotypes such as hypersensitivity to cross-
linking agents, accumulation in G2 phase and increased chromosomal breakage after exposure 
to MMC (mitomycin C),  as previously observed in cells lacking known Fanconi anaemia 
proteins. Mitomycin C is an anti-tumour alkylating drug, with an potential of forming cross-
links within the DNA. The Fanconi anaemia pathway is important in the repair of inter-strand 
crosslinks (ICLs) and the maintenance of genome instability. Based on two reports, there is a 
possibility of PFAP playing a key role in regulating histone lysine methylation, via its 
interaction with the SET/COMPASS like histone methyltransferases SET1A/SET1B. It was 
previously shown that PFAP interacts with SET1B. However, unpublished studies carried out 
by our laboratory have suggested that PFAP interacts with SET1A. Therefore, we wished to 
investigate these interactions in further detail.  In this study, we demonstrated that PFAP 
interacts with SET1A histone methyltransferase, but not SET1B. In addition, we studied 
localisation of SET1A to the sites of ICL repair sites, as proteins involved in DNA repair 
often relocalises to form sub-nuclear foci in response to DNA- damaging agents such as 
MMC.  Immunofluorescence staining reveals that FLAG-tagged SET1A and RAD51 each 
localises to a largely non-overlapping regions of nucleus, suggesting that both FLAG-SET1A 
and RAD51 each targets specific genomic sites and therefore, has distinct functions in ICL 
repair. Finally, we demonstrated that the Fanconi anaemia proteins: FANCD2 and FANCJ 
interacts with PFAP, thus indicating that PFAP is involved in FA pathway.  
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1.0 Introduction 
Fanconi Anaemia (FA) pathway functions to protect the cell against DNA highly toxic 
lesion termed interstrand crosslinks (ICLs). This project involves characterization of a novel 
gene called PFAP, whose loss would phenotypically resembles loss of Fanconi anaemia 
proteins involved in the Fanconi anaemia pathway. This project include investigating in vitro 
interactions of PFAP with components of histone methyltransferase complexes and other FA 
proteins, to elucidate the role of PFAP in histone methylation and with other fanconi anaemia 
proteins involved in FA pathway.  
1.1 Introduction to DNA damage and repair 
Our cellular genomes are under constant attack from variety of DNA damaging agents 
that could pose a threat to genomic integrity (Bernstein et al., 2013). DNA damage is a 
change in the structure of DNA; this change can be a chemical addition or disruption to a base 
possibly, giving rise to bulky adducts or a break within the phosphate backbone of DNA (See 
Hoeijmakers, 2001 for review). Such breaks may affect single strand or both strands of DNA 
(See Hoeijmakers, 2001; Ciccia and Elledge, 2010 for reviews). DNA damaging lesions are 
caused by environmental mutagens (UV, ionizing radiation and various genotoxic causes), by 
product(s) of normal cellular metabolism (reactive oxygen species, superoxide dismutase and 
glutathione peroxidase) and spontaneous disintegration of chemical bonds in DNA caused by 
physiological conditions such as hydrolysis, deamination. Consequences of lesions caused by 
all of the above sources could trigger cell cycle arrest, induction of apoptosis, inhibition of 
transcription and replication and also cause mutations resulting in oncogenesis (Hoeijmakers, 
2001).  
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Double strand breaks (DSBs) are the most potent lesions, and one unrepaired DSB is 
sufficient to cause apoptosis due to its ability to inhibit transcription, prevent DNA replication 
and cause problems during chromosome segregation (Hoeijmakers, 2001; Chapman et al., 
2012). Due to the above reasons, DSBs are referred as one of the primary causes of cancer 
(Jackson and Bartek, 2009; McKinnon, 2009). Therefore, DNA breaks need to be repaired 
efficiently by specific DNA repair mechainsms. DNA damage recognition repair is carried out 
by activities of many different enzymes including nucleases, kinases, demethylases, 
polymerases and phosphatases which act in various repair mechanisms such as nucleotide 
excision repair, base excision repair, homologous recombination, non-homologous end 
joining, mismatch repair (Ciccia and Elledge, 2010) (Figure 1.1).  
 
1.1.2 DNA repair mechanisms 
Eukaryotic organisms have evolved sophisticated, interwoven DNA repair systems to 
cope with the injuries "imposed on a cell’s vital genetic information" (Hoeijmakers, 2001). 
The five main types of repair pathways in mammals include nucleotide-excision repair 
(NER), base-excision repair (BER), homologous recombination (HR) and non-homologous 
end joining (NHEJ) (Reviewed by Lindahl and Wood, 1999; Hoeijmakers, 2001) (Figure 1.1). 
While these pathways deal with different types of lesions, however, there is a considerable 
overlap between these mechanisms (Martin et al., 2008). For example, NER deals with range 
of helix-distorting lesions arising mostly by exogenous agents, and some caused by oxidative 
lesions. Most of the oxidative lesions are mostly repaired by BER, the repair pathway 
responsible dealing small chemical alterations of bases (Pecorino, 2012) (Figure 1.1). 
Furthermore, if these single strand breaks (ssDNA) are not repaired by BER, then these 
ssDNA breaks may form into DSBs, which are then repaired by homologous recombination 
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repair or non-homologous end joining (Martin et al., 2008).  Homologous recombination 
dominates in S and G2 when the DNA is replicated, providing a second copy of the sister 
chromatid for aligning the breaks. In contrast, non-homologous end joining is most prevalent 
in the G1 phase of the cell cycle, where a second copy of sister chromatid as template is not 
available (Pecorino, 2012; Takata et al., 1998).  Each of these repair mechanism mentioned 
above forms part of a series of orchestrated pathways called the DNA damage response 
(DDR) (Spycher et al., 2008; Ciccia and Elledge, 2010).   
 
1.2 DNA Damage Response (DDR) 
The DDR is a highly orchestrated signal transduction pathway that acts to sense and 
repair DNA damage; and responds in a well orchestrated way. The activation of DDR 
pathway is dependent on  the type of DNA damage that occurs and the activation of  apical 
kinases called ATM (ataxia telangiectasia mutated), activated in response to DSBs, ATR 
(ataxia telangiectasia- Rad3 related) activated in response to exposed single stranded DNA 
and DNA-PKcs (DNA-dependent protein kinase catalytic subunits). These apical kinases 
activate various downstream kinases and proteins that coordinate the arrest of cell cycle 
progression, cellular senescence and in some cases apoptosis to maintain the genomic 
integrity (Spycher et al., 2008; Sulli et al., 2012).  
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Figure 1.1: Schematic diagram of common DNA damage-
inducing agents and repair mechanisms.  Examples of DNA 
damage inducing agents (blue), types of lesions induced by DNA 
damaging agents (red) and mechanisms involved for the removal 
of the lesions (green). (Adapted from Hoeijmakers, 2001). 
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1.3 Fanconi Anaemia (FA) 
1.3.1  Clinical phenotypes of FA 
Fanconi anaemia (FA) is an autosomal recessive disorder affecting almost 1 in 
100,000 births (Moldovan and D'Andrea, 2009; Kottemann and Smogorzewska, 2013). Due 
to the diversity of clinical phenotypes presented by patients diagnosed with FA, it is termed as 
"clinically heterogenous"(Moldovan and D'Andrea, 2009). Fanconi anaemia was initially 
described by Swiss paediatrician Guido Fanconi in 1927; and characterized as aplastic 
anaemia with short stature, hypogonadism and skin pigmentation (Fanconi, 1927). Several 
clinical phenotypes are observed in FA patients including skeletal abnormalities (primordial 
dwarfism, congenital defects), progressive bone marrow failure, pancytopenia, microcephaly 
(Garcia-Higuera et al., 2001; Tischkowitz and Hodgson, 2003). Importantly, patients with FA 
also exhibits an increased risk of developing acute myeloid leukaemia (AML) and squamous 
cell carcinoma of head and neck, although the underlying mechanisms remain unclear 
(Moldovan and D'Andrea, 2009).  
1.3.2 Cellular phenotypes of FA 
In addition to the clinical manifestations described above, the most striking feature of 
cells defective in the FA pathway is their tendency to exhibit hypersensitivity to DNA cross-
linking agents such as mitomycin C (MMC), cisplatin, dipeoxybutane etc. This crucial 
phenotype underlines the importance of proteins in the FA pathway in repairing inter-strand 
crosslinks (described in section 1.3.3-1.3.4) induced by these cross-linking agents (Moldovan 
and D'Andrea, 2009). Accordingly, exposure to these crosslinking agents can also increase the 
frequency of chromosomal breakage and radial chromosomes in FA cells, (Figure 1.2).  Thus, 
Fanconi anaemia is referred as genomic instability disorder.   
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Figure 1.2: Representative image of a metaphase spread in 
cells defective for the FA pathway after MMC exposure. 
Chromosome breakage and radial chromosomes are indicated in 
red. (Adapted from Moldovan and D’Andrea, 2009) 
                                                              7   
 Therefore, cells defective in FA are becoming a highly valued model system to study ICL 
repair.  
1.3.3 Fanconi anaemia proteins 
Thus far, sixteen Fanconi anaemia gene products have been identified (also known as 
complementation groups: FANCA, B, C, D1, D2 E, F, G, I, J, L, M, N, O, P, Q) (Refer to 
table 1.0 for more details). Eight of these FA proteins (FANCA, FANCB, FANCC, FANCE, 
FANCF, FANCG, FANCL) forms FA core complex of the fanconi anaemia pathway, which 
gets recruited to the chromatin for the mono-ubiquitination of FANCD2-FANCI, once ICL 
lesion is detected by FANCM and accessory protein called FAAP24. Other FA proteins such 
as FANCD1 (BRCA2), FANCN (PALB2), FANCO (paralog of RAD51) and FANCJ are 
involved in the homologous recombination repair (downstream pathway of FA pathway). 
FANCP and newly identified FA protein called FANCQ (Walden, 2014) are involved in the 
nucleolytic activity downstream of mono-ubiquitination of FANCD2. FANCP (SLX4) forms 
the scaffold or co-factor for the other nucleases: XPF-ERCCI and MUS81-EME1 for 
nucleolytic incision stages of FA pathway (table 1.0) (See reviews by Moldovan and 
D'Andrea, 2009).   
1.3.4 The FA pathway and ICL repair 
As a result of numerous studies, it is now clear that components of the FA pathway are 
involved in the both of repair of interstrand crosslinks. In this section, I will introduce the role 
of FA proteins in ICL repair. 
ICLs are highly toxic lesions that covalently link two strands of DNA, when exposed 
to DNA-cross-linking agents such as MMC, cisplatin and DEB etc (Ciccia and Elledge, 
2010).  The presence of these crosslinks inhibits DNA replication, as ICL blocks replication 
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forks and also interfere with gene transcription. Regardless at which stage of the cell cycle 
ICL has  formed, cells with ICLs arrest in the S phase of the cell cycle, allowing time for the 
ICL to be repaired before replication can continue (Akkari et al., 2000; Ward et al., 2012). 
Due to their ability to inhibit vital cellular processes, ICLs needs to be repaired to prevent 
fatal cellular consequences.  
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Table 1.0: List of Fanconi anaemia proteins and their functions. (Adapted from Kottemann 
and Smogorzewska, 2013; Walden and Dean, 2014 ). 
FA genes Function Link to Fanconi 
anaemia 
FANCA 
FANCB 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCI 
FANCG 
FANCL 
FANCM 
Core complex 
member and 
required FANCD2- 
FANCI 
ubiquitination; 
FANCL is an E3 
ubiquitin ligase 
Genes mutated in 
Fanconi anaemia 
FANCD1 
(BRCA2) 
HR mediator; 
downstream of 
FANCD2-FANCI 
ubiquitination 
Genes mutated in 
Fanconi anaemia 
FANCJ (BRIP1) Fanconi anaemia, 
homologous 
recombination, 3' 
to 5' DNA helicase 
Genes mutated in 
Fanconi anaemia 
FANCN (PALB2) Fanconi anaemia, 
homologous 
recombination and 
promotes BRCA2 
Genes mutated in 
Fanconi anaemia 
FANCO 
(RAD51C) 
Homologous 
recombination 
Genes mutated in 
Fanconi anaemia 
FANCP (SLX4) Fanconi anaemia, 
coordinates XPF-
ERCC1, MUS81-
EME1 and SLX1 
nucleases 
Genes mutated in 
Fanconi anaemia 
FAN1 Interstrand 
crosslink repair 
Interacts with I-D2 
complex 
FANCQ (ERCC4) Interstrand 
crosslink and 
nucleotide excision 
repair 
Gene mutated in 
Fanconi anaemia 
 
ICL lesions are repaired through the orchestrated actions of various nucleases, translesion 
polymerases and many more DNA repair factors, which are co-ordinated by members of the 
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FA pathway. Although the precise mechanisms are not yet understood, current evidence 
suggests that ICL maybe repaired  in two ways -  replication dependent and replication 
independent (Figure 1.3) (Kottemann and Smogorzewska, 2013; Huang and Li, 2013). In the 
absence of active replication forks, ICL lesions are repaired independent of replication and 
recombination (RIR). This repair process mainly occurs in cells during G0/G1 phase of the 
cell cycle. RIR is a "critical process to maintain genomic integrity and allowing transcription 
in non-dividing or slowly dividing cells as suggested by Williams and co (2012). NER factor 
termed XPC recognises ICL lesion. This result in the recruitment of NER nucleases: XPF-
ERCC1 and XPG to initiates unhooking step on one of the damaged strand by introducing 
dual incisions on both sides of the ICL lesion, followed by translesion synthesis in which a 
translesion polymerase zeta (TLS pol ζ) fills the gap on one of the damaged strand and 
exonucleases excises the unhooked ICL lesion to complete the repair process (Figure 1.3)  
(Huang and Li, 2013). 
  
On the other hand, replication and recombination dependent pathway is activated when an 
ICL lesion is encountered during S phase and the converging forks from different directions 
stalls a few nucleotides from a particular ICL lesion site. Subsequently one fork moves 
forwards and stops just before lesion (Moldovan and D'Andrea, 2009). The recruitment of 
endonucleases allows excision of the region surrounding the ICL, and forming a DSB. This 
results in the uncoupling of one sister chromatid from the other, followed by the unhooking of 
the cross-links by endonucleases, bypassing of the unhooked lesion by translesion 
polymerases which are able to replicate through DNA lesions (Neidzweidz et al., 2004). The 
DSB formed by endouclease activity is repaired by homologous recombination and invasion 
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of the repaired chromatid by the sister (Figure 1.4). Fanconi anaemia pathway is the classic 
example of replication-dependent repair of ICLs. 
1.3.4.1 Replication dependent ICL repair - FA pathway 
Recruitment of the FA core complex and mono-ubiquitination of FANCI-
FANCD2 
One of the crucial stages in the activation of the FA pathway during replication-
dependent ICL repair is the mono-ubiquitination of FANCI- FANCD2 complex by the FA 
core complex. The FA proteins form the FA core complex (refer to section 1.3.3) and acts as a 
multi-subunit ubiquitin ligase. The FA core complex is recruited to the chromatin during S 
phase of the cell cycle for FANCI-FANCD2 monoubiquitination complex, by FANCM and 
FAAP24, upon ICL encounter (Reviewed by Patel and Joenje, 2007; Ciccia et al., 2007; 
Moldovan and D'Andrea, 2009; Kottemann and Smogorzewska, 2013) (Figure 1.4).  
 
Prior to mono-ubiquitination, phosphorylation of FANCI at SQ and TQ sites is required for 
the efficient ubiquitination of I-D2 complex (Ishiai et al., 2008; Knipscheer et al., 2009). 
Mono-ubiquitination of FANCD2 and FANCI occurs at lysines lys561 and lys523 
respectively through the action of the PHD domain of FANCL and UBET E2 ubiquitin 
enzyme (Figure 1.4) (Taniguchi et al., 2002; Smogorzewska et al., 2007).  
Upon mono-ubiquitination on lys561, FANCD2 relocalizes to chromatin as DNA 
damage foci, where it binds and co-localises with BRCA2 (Garcia-Higuera et al., 2001; 
Taniguchi et al 2002; Wang et al., 2004) and thus enable FANCD2 to orchestrate the actions 
of downstream repair pathway including translesion bypass, nuclease recruitment and 
homologous recombination repair (Figure 1.4) (Moldovan and D'Andrea, 2009). 
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Figure 1.3: Replication and recombination independent ICL 
repair. A. Replication independent interstrand cross link repair. 
Pathway comprises by recognition of ICL lesion by NER factor 
XPC. XPF-ERCC1 and XPG unhook the lesion, translesion 
polymerase zeta fills the gap one of damaged strands and the 
unhooked lesion is removed or excised by exonucleases. 
(Adapted from Huang and Li, 2013). 
XPC 
XPF-
ERCCI 
XPG 
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Figure 1.4: Replication-
dependent ICL repair.  
The core complex is made up of 
Fanconi anaemia proteins and 
accessory proteins (such as 
FAAP24 and FAAP20). Upon 
detection of the crosslink, FANCM 
is recruited and activated by ATR-
mediated phosphorylation, 
recruiting the core complex to 
chromatin. This complex 
ubiquitinates the I-D2 complex. 
Upon monoubiquitination, 
ubiquitinated I-D2 complex 
localizes to the chromatin and 
orchestrates the action of 
downstream repair factors 
including SLX4, XPF, and 
MUS81/EME1 that functions at the 
site of DNA damage to make 
incisions on either side of the 
lesion strand. On the incised 
strand, TLS polymerases are 
recruited to by-pass the unhooked 
crosslink. This break is then 
repaired by BRCA2, PALB2, and 
RAD51C via homologous 
recombination. (Adapted from 
Ciccia and Elledge, 2010) 
                                                              14   
Regulation of D2-I mono-ubiquitination 
The regulation of the FA pathway is poorly studied. However, USP1 (ubiquitin 
specific peptidase 1) protein is involved in the regulation of FA pathway via deubiquitination 
of FANCD2 (Patel and Joenje, 2007; Moldovan and D'Andrea, 2009; Kottemann and 
Smogorzewska, 2013).  
Under normal circumstances, i.e. in the absence of DNA damage, mono- ubiquitination of 
FANCD2 is kept under control by USP1 deubiquitylating enzymes, with the help of UAF1 
(WD repeat containing protein) by forming USP1-UAF1 complex.  Upon DNA damage, the 
transcription of USP1 is turned off and the USP1 protein present in the cells are degraded by 
the proteasome and thus, resulting in excessive accumulation of mono-ubiquitinated 
FANCD2 (Moldovan and D'Andrea, 2009). However, even in the absence of USP1, excess 
FANCD2 are still unable to localise to foci, even though they are able to accumulate on the 
chromatin. This suggests that USP1 is required for the completion of DNA repair and / or re-
localisation of FANCD2 to the sites of ICL damage.  
Nucleolytic removal of the ICL and TLS 
The initial incisions that unhook the cross-links are performed by NER endonculeases: 
XPF- ERCC1 and Mus81-EME1, with help of SLX4 (FANCP) acting as a scaffold or co-
factor. ICL nucleolytic cleavage is performed in highly coordinated manner, with Mus81-
EME1 performing the initial incision at the 3' end of the lesion and ERCC1-XPF performs 
secondary incision at 5' end cleavage (de Winter and Joenje, 2008; Ciccia et al., 2008).  
 
Translesion DNA polymerases are also important components of ICL repair. Studies 
in Xenopus laevis egg extracts demonstrated that the translesion polymerases including 
polymerase Rev1 and polymerase polζ (comprised of Rev3 and Rev7) have essential roles in 
the removal of ICL. Upon ICL unhooking, Rev1 inserts a base into the position across the 
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ICL lesion on the complementary strand, followed by the polζ to extend the unrepaired strand  
(Huang and Li, 2013). 
Homologous Recombination Repair (HR) 
FANCD1 (BRCA2), FANCN (PALB2) and FANCJ do not form the part of the core complex 
required for the mono-ubiquitination of FANCD2-FANCI, but are required for homologous 
recombination repair of the ICL. Chromatin bound ubiquitinated FANCD2-FANCI, recruits 
BRCA2, PALB2 (interactor of BRCA2) and Rad51 to initiate ICL repair via homologous 
recombination (HR). BRCA2 relocalises with mono-ubiquitinated FANCD2 and thus, 
initiates homologous recombination by promoting assembly of RAD51 onto ssDNA. This 
RAD51-ssDNA complex then invades homologous duplex DNA to generate a displacement 
(D-loop) loop. At the D-loop, DNA synthesis occurs to extend the invading strand and finally, 
recombination process occurs via double holiday junction (Pecorino, 2012). FANCJ (BRIP1 
or BACH1) is the second helicase in the FA pathway. FANCJ interacts with BRCT domains 
of BRCA1 and localizes to DNA repair structures containing BRCA2 and RPA (Replication 
Protein A) (Moldovan and D'Andrea, 2009). "Although, the function of FANCJ in ICL repair 
is unknown,  its 5' to 3' helicase activity is likely used to remodel DNA structures, thus 
facilitating or activating repair"(Moldovan and D'Andrea, 2009).  
The roles of FA proteins are not limited to ICL repair, but are also involved in the 
stabilisation of replication fork and tumour suppression (de Winter and Joenje, 2009; 
Kottemann and Smogorzewska, 2013).  
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1.3.5 FA and stabilisation of replication fork 
Apart from its role in interstrand cross-link repair, FA pathway is also important for 
the protection and stabilisation of DNA replication forks under replicative stress (Moldovan 
and D'Andrea, 2012; Schlacher et al., 2012). In addition to ICLs, FA pathway can also be 
activated by replicative stress agents mainly hydroxyurea (HU) and ultraviolet light (UV). 
Schlacher et al has demonstrated that components of the FA pathway are required for the 
stabilisation and protection of replication forks from nucleolytic degradation, thus preventing 
genomic instability and tumorigenesis (Schlacher et al., 2012). Schlacher and co-workers 
demonstrated that mono-ubiquitinated FANCD2 (FANCD2-ub) is functionally epistatic with 
BRCA2 and Rad51, thus providing a complete understanding of Fanconi anaemia proteins 
involved in maintaining replication fork stability from ICL and other DNA stresses (Schlacher 
et al., 2012). FANCD2-ub interacts with proliferating cell nuclear antigen (PCNA) (Howlett 
et al., 2009), BRCA2, RAD51.  In the absence of FANCD2, BRCA2, Rad51, are insufficient 
to stabilise replication fork, therefore FANCD2, acts as mediator for the association of 
BRCA2/Rad51 with PCNA, for stabilising replication forks and preventing it from collapsing 
(Schlacher et al., 2012). However, in the absence of BRCA2 and FANCD2, Rad51 filaments 
are sufficient to for fork protection. This is because of gain of function by Rad51 mutant or 
overexpressed Ras51, results in the formation of hyperfilaments of Rad51 which stabilises 
stalled replication fork in the absence of BRCA2 and FANCD2 (Morrison et al., 1999).  
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1.4 PFAP (Putative Fanconi Anaemia Protein) 
Our laboratory has discovered a novel uncharacterized protein, that we have termed 
PFAP (Putative Fanconi Anaemia Protein). PFAP is a large nuclear protein of 3051 amino 
acid and approximately 550 KDa in size. PFAP has few identifiable protein domains, but 
interestingly contains several ATM/ATR phosphorylation sites scattered throughout PFAP 
(Matsuoka et al., 2007), mainly located within the central region of PFAP (Figure 1.4). In 
addition, the N-terminus of PFAP contains a region of sequence homologous to the mitotic 
protein BOD1 (Biorientation Of Cell Division 1) (Porter et al., 2007) and the yeast 
COMPASS protein Shg1, that we have named the Shg1-homology (Shg1H) domain (Figure 
1.4). 
According to unpublished data from our laboratory, cells lacking PFAP-defective cells exhibit 
similar cellular phenotypes to cells lacking Fanconi anaemia proteins (as mentioned in earlier 
sections 1.3.2), including  hypersensitivity to DNA crosslinking agents, accumulation in the 
G2 phase after MMC and increased chromosomal breakages after exposure to MMC. 
 
Thus far, there is no literature describing PFAP and its role in maintaining genomic stability. 
However, there are two reports which raises the possibility that PFAP may play role in the 
regulating histone methylation, via interactions with the methylated forms of Lys4 of histone 
H3 (Eberl, 2013), and through a possible interaction with SET/COMPASS like histone 
methyltransferases SET1A/SET1B (Nuland et al., 2013). Recent studies carried out by 
Nuland and co-workers (2013), demonstrated that PFAP and BOD1 interacted with SET1B 
(Nuland et al., 2013). However, data from our laboratory suggests that PFAP interacts with 
SET1A, but not SET1B. Thus, this project is aimed to investigate this interaction in further 
detail.  
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Figure 1.5: Schematic representation of PFAP and its 
domains. The Shg1H domain, which is homologous to both the 
yeast COMPASS member Shg1, and the human protein BOD1, is 
indicated in grey. The N-terminal ‘Pro-rich domain’ is in blue, and 
the C-terminal A-T hook/NLS domain is in orange. Known 
ATM/ATR phosphorylation sites are encircled (Matsuoka et 
al.,2007), and putative ATM/ATR phosphorylation sites are 
indicated with arrows. 
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1.5 The SET1A and SET1B histone methyltransferase 
SET1A and SET1B comprise two of the six SET/COMPASS like-histone 
methyltransferases (HMTs) (Figure 1.6), responsible for regulating global levels of 
methylation of lysine four on histone H3 (H3K4). SET1A and SET1B, along with the other 
four histone methyltransferase complexes, shares non-catalytic subunits such as WDR5, 
Rbbp5, ASH2L and DPY30 also known as (WRAD) Cfp1, WDR82 (Figure 1.6). The WRAD 
forms a sub-complex and associates with catalytic subunit of HMT complexes (Dehe et al., 
2006; Nuland et al., 2013). 
 
Both SET1A and SET1B contains SET-domain, post-SET domain at their carboxyl terminal 
and RNA recognition motif at the amino terminal end (Figure 1.7). SET1A and SET1B also 
exhibit 39% identity and 56% similarity to their counterpart yeast Set1 protein (Figure 1.7) 
(Lee et al., 2007). Although both SET1A and SET1B are similar, confocal microscopy 
reveals that both SET1A and SET1B exhibit non-overlapping sub-nuclear localization. This 
shows both target distinct set of genomic sites and therefore, has distinct functions in 
regulation of chromatin structure and gene expression (Lee et al., 2007).  
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PFAP 
Figure 1.6: SET1A/SET1B histone methyltransferase complexes.  
The SET1A (upper) and SET1B (lower) histone methyltransferase 
complexes consists of common non-catalytic subunits and the unique 
enzymatic subunits SET1A and SET1B. NB: PFAP and BOD1 are 
illustrated to be part of the SET1B-containing complex in this diagram, 
although our data indicates that PFAP is a part of the SET1A-containg 
complex (Adapted from Nuland et al., 2013).  
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Figure 1.7: Schematic representations of human SET1A/SET1B 
and yeast SET. The enzymatic domains are indicated, with the RRMs 
(RNA recognition motif) in blue, and the catalytic SET domains in 
green. (Adapted from Lee et al., 2013). 
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1.5.1 Histone methylation by SET1A/SET1B 
 
"Chromatin" is the structure in which DNA is embedded, and the importance of 
chromatin structure is increasingly understood to be crucial to the DDR and how lesions are 
recognised and repaired (Jorgensen et al., 2013).  
Chromatin is composed of nucleosomes, which in turn is composed of  an octamer of four 
core histone proteins namely H2A, H2B, H3, H4 (Review by Martin and Zhang, 2005). 
Histone proteins are subject to various posttranslational modifications (PTMs) such as 
phosphorylation,  methylation, acetylation, ubiquitination, sumoylation  that are crucial in 
maintaining the chromatin structure and regulating gene expression but which are important 
in DNA repair, DNA replication and cell division (Review by Martin and Zhang, 2005).  
 
Histone methylation is the process where methyl groups are transferred to amino acids 
of histone proteins. Histone methylation occurs on lysine and arginine residues on histone 
three and histone four and are catalysed by enzymes belonging to three distinct families of 
proteins: Arg residues are methylated by PRMT (Protein Arginine Methyltransferases), and 
lysine residues are methylated by SET-domain methyltransferases (SET1A) and non-SET 
domain proteins (DOT1/DOT1L) (Zhang and Reinberg, 2001; Bannister and Kouzarides, 
2005). "Methylated lysines and arginine residues act to recruit effector proteins to specific 
genomic loci to impose their specific regulatory function upon the underlying DNA" 
(Jenuwein and Allis, 2001).  
A large body of evidence has demonstrated that histone lysine methylation regulates 
gene expression by acting as a transcriptional activator or transcriptional repressor, depending 
on the site of the methylation (Zhang and Reinberg, 2001; Martin and Zhang, 2005).  To date, 
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there is no published evidence that methylation of H3K4 by SET1A or SET1B regulates the 
DDR, or that they contribute to maintaining genomic instability. This is currently under 
investigation by our laboratory. 
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Aims of the Project 
As part of our ultimate goal, which is to characterise the function and role of PFAP in 
the DDR, and in particular its role in the FA pathway, we wished to explore further 
interaction between SET1A and PFAP. Given our knowledge outlined above, this project 
therefore had three main objectives: 
 
1.  To examine the interaction of PFAP and SET1A in vitro, using two approaches: 
 To confirm previous data obtained in our laboratory, we will first examine the 
interaction of PFAP with the histone methyltransferases SET1A, SET1B in 
vitro by immunoprecipitation analyses 
 
  To extend and complement ( a), we aim to determine the area(s) of PFAP 
necessary for interaction with SET1A using GST-tagged fragments of PFAP in 
GST-pull down assays 
 
2. To determine whether PFAP interacts with other known Fanconi anaemia proteins by 
co-immunoprecipitation 
 
3. To study whether SET1A localises to Rad51-containing sub-nuclear foci induced by 
mitomycin c exposure by immunofluorescence 
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2.0 Materials and Methods 
2.1 Plasmids 
The following plasmids were used in this study 
Plasmid Origin/Supplier Brief description 
pGEX-3X GE Healthcare Bacterial vector for expressing 
GST fusions under the control 
of tac promoter. Encodes Amp
R 
pGEX-PFAP-F1 Dr. M.Higgs/Dr. E. Miller 
University of Birmingham 
Amino acids 1-600 of PFAP 
cloned into the SalI-NotI 
restriction sites of pGEX-3X 
pGEX-PFAP-F2 Dr. M.Higgs/Dr. E. Miller 
University of Birmingham 
Amino acids 500-1000 of 
PFAP cloned into the SalI-NotI 
restriction sites of pGEX-3X 
pGEX-PFAP-F3 Dr. M.Higgs/Dr. E. Miller 
University of Birmingham 
Amino acids 900-1500 of 
PFAP cloned into the SalI-NotI 
restriction sites of pGEX-3X 
pGEX-PFAP-F4 Dr. M.Higgs/Dr. E. Miller 
University of Birmingham 
Amino acids 1400-2000 of 
PFAP cloned into the SalI-NotI 
restriction sites of pGEX-3X 
pGEX-PFAP-F5 Dr. M.Higgs/Dr. E. Miller 
University of Birmingham 
Amino acids 1900-2500 of 
PFAP cloned into the SalI-NotI 
restriction sites of pGEX-3X 
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pGEX-PFAP-F6 Dr. M.Higgs/Dr. E. Miller 
University of Birmingham 
Amino acids 2400- 3051 of 
PFAP cloned into the SalI-NotI 
restriction sites of pGEX-3X 
 
2.2 Cell culture 
HeLa-FLAG-SET1A cells were from Prof.D.Skalnik (IUPUI, Indianapolis, USA), and 
were cultured in Dulbecco's Modified Eagle's Media supplemented with 10 % tetracycline-
free fetal calf serum (Gibco, UK). U2OS-FLAG-SET1A cells were created by Dr. G. Stewart 
(University of Birmingham), and cultures in McCoys' media supplemented with 10 % 
tetracycline-free fetal calf-serum. Where appropriate, doxycycline was added to cell culture 
medium at 1 μg/ml. Mitomycin c was from Sigma Aldrich (UK), and was used at a final 
concentration of 50 ng/ml. 
 
2.3 Antibodies 
The following antibodies were used in this study 
Table 2.1: List of primary antibodies used  
Primary 
antibodies 
Host Dilution for 
immunoblotting 
Application Source 
SET1A Rabbit 1 in 500 IP, pull down Home-made by 
David Skalnik, 
USA 
SET1B Rabbit 1in 250 IP, pull down Bethyl laboratories 
(USA) 
FLAG-SET Mouse 1in 500 IF Bethyl laboratories 
(USA) 
RAD51 Rabbit 1in 50 IF Calbiochem (UK) 
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PFAP Rabbit 1in 500 IP Santa cruz 
Biotechnology 
(UK) 
FANCM Rabbit 1in 500 IP Fanconi anaemia 
Research funds 
(USA) 
FANCJ Rabbit 1in 500 IP Fanconi anaemia 
Research funds 
(USA) 
FANCD2 Mouse 1in 500 IP Santa cruz 
Biotechnology UK 
 
 
Table 2.2: List of secondary antibodies used 
Secondary 
antibodies 
Host Dilutions Application Source 
HRP Conjugate 
Reliablot 
Rabbit 1in 3000 IP, pull 
downs 
Bethyl laboratories 
(USA) 
Fluorescein FITC Goat  1in 500 IF Life technologies 
(UK) 
Alexa Fluor® 595 Mouse 1 in 500 IF Life technologies 
(UK) 
Polyclonal anti-
goat IgG/ HRP  
Rabbit 1in 3000 IP Dako (UK) 
Polyclonal swine 
IgG/HRP  
Mouse 1in 1000 IP Dako (UK) 
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2.4 Chemicals 
Chemicals were purchased from Sigma Aldrich (UK) except the exceptions listed 
below. Glycine was from VWR (UK), glutathione was from Roche Biochemicals (USA) and 
acrylamide was purchased from BioRad (UK).  
 
2.5 Bacterial transformations 
 One hundred microlitres of BL21 Escherichia coli competent cells (Agilent 
Technologies) were aliquoted into prechilled tubes. To each set of competent cells, 2 µl of 
diluted β-mercaptoethanol (Agilent Technologies, UK)  and approximately 10-50 ng of 
pGEX-3X or pGEX-3X encoding PFAP fragments (refer to section 2.1) were added. Cells 
were placed on ice for 30 minutes, heat-shocked for 25 seconds at 42 °C and incubated on ice 
for another 2-3 minutes. Eight hundred microlitres of SOC medium was added to the 
transformation reactions and incubated for 1 h at 37 °C in a shaking incubator at 200 rpm. 
After incubation, 100 µl of transformation reactions were placed onto agar plates containing 
500 µl of ampicillin and left to form colonies overnight at 37 °C.  
 
2.6 Small-scale protein expression 
Single ampicillin-resistant colonies were picked from each agar plates and grown in 
15 ml of Luria Broth (LB) supplemented with 100 µg/ml ampicillin at 30 C, until they 
reached an optical density (OD600nm) of 0.4-0.6. Once the expected OD was reached, IPTG 
was added to a final concentration of 1 mM and incubated for 3 h at 30 C.  
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2.7 Large scale protein expression  
Single bacterial colonies were picked and grown as described in section 2.6. Fifteen 
mililitre starter cultures were grown for 6-7 hours at 30 C and 2 ml of this culture was 
aliquoted into 500 ml of LB supplemented with 100 µg/ml ampicillin. Bacterial cultures were 
incubated at 30 C, until they reached an optical density (OD600nm) between 0.4-0.6. Once the 
expected OD was reached, IPTG was added to a final concentration of 1 mM and incubated 
for 3 hours at 30C. Bacterial pellets were collected by centrifugation x g for 20 minutes at 4 
°C and bacterial pellets frozen down at -80 C until purification.  
  
2.8 Purification of recombinant proteins 
Prior to purification, Glutathione Sepharose beads (GE Healthcare, UK) were 
centrifuged at  x g  for 30 seconds to remove excess ethanol and washed  three times with 10 
minute washes of 10 ml of PBS + 1 % Triton X-100 and twice in 10 ml of PBS +1 mM 
EDTA for ten minutes. Beads were left in PBS + 1 mM EDTA until further use.  
 
Bacterial pellets were resuspended in lysis buffer (PBS +1 % Triton X- 100, plus 
protease inhibitor tablets) and lysed by sonicating the samples six cycles at max power for 20 
seconds on ice.  To each cell lysates 4 ml pre-prepared glutathione sepharose beads were 
added and the mixture was incubated for 2 h on a rotator at 4 C. After 2 h, lysates were spun 
and second set of GST beads were added and incubated for further 2 h.  After centrifugation 
the recovered beads were washed three times with 40 ml of PBS+ 1 % Triton X-100 + 1 mM 
EDTA for ten minutes each. Beads were further washed two times with 10 ml of PBS+1 mM 
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EDTA. After the last wash, the beads were resuspended in 4 ml of elution buffer (25 mM 
Glutathione pH 8, 2.5 ml of 50 mM Tris pH 8) and incubated for another 1 hour. The eluted 
protein was transferred into pre-chilled 15 ml tube and protein re-eluted with a two further 
incubations of 4 ml of elution buffer.  All 3 eluted proteins fractions were transferred into 
dialysis tubing (pre-boiled in 2 mM EDTA and 3 % sodium bicarbonate; and washed three 
times in distilled water before use) and dialysed overnight in dialysis buffer (50 mM Tris pH 
7.5, 200 ml of 10 % glycerol, 2 ml of 1 mM DTT and 1698 ml of distilled water). The 
concentration of eluted dialysed proteins was measured by Bradford assay (Bio-rad, UK) and 
estimated by Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) in 
conjunction with pre-diluted BSA protein standards. 
 
2.9 GST pull down assays  
For GST pull-down assays,  5 μg of purified GST or GST fusion proteins were  
incubated with 1 ml of  pre-cleared HeLa nuclear extracts (Cilbiotech, Belgium) at 4 °C for 3 
h.  Glutathione sepharose beads (pre-washed in NTN buffer (100 mM NaCl, 20 mM Tris pH 
7.5, 0.05 % NP40)) were then added and extracts were further incubated at 4 °C for another 4 
hours. The beads were then washed three times with 1 ml of NTN buffer and resuspended in 
2X SDS loading buffer (Bio-Rad) and boiled for ten minutes at 95 °C before analysing by 
SDS-PAGE and immunoblotting.  
 
2.10 Immunoprecipitation 
Five micrograms of immunoprecipitating antibody or IgG was added to 200 µl of pre-
cleared HeLa nuclear cell extracts and incubated at 4 °C for 3 h. Twenty five microlitres of 
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protein A sepharose beads (GE Healthcare, UK) were added and the lysates  incubated at 4 °C 
for further 2 h. The immune complexes were washed with three times with 1 ml NTN buffer 
and resuspended in 2X SDS loading buffer, boiled at 95 °C for ten minutes, before analysing 
by SDS-PAGE and western blotting.  
 
2.11 Whole cell extract preparation 
Whole cell extracts (WCE) were prepares from cultured cells using UTB buffer (8 M 
urea, 50 mM tris, 150 mM β-mercaptoethanol). Briefly, approximately 0.5 x 107 were 
trypsinsed, washed in ice cold PBS, and resuspended in 150 µl UTB. Lysates were sonicated 
for 2 cycles at max power for 5 seconds on ice, and protein concentrations determined by 
Bradford assay.  
 
2.12 Sodium-dodecyl sulphate polyacrylamide (SDS-PAGE) gel 
electrophoresis 
GST pull downs, immunoprecipitates or whole cell extracts were analysed by SDS-
PAGE. Briefly 50 μg of WCE, or the entirety of GST pull downs or immunoprecipitates were 
analysed on 6% Tris-bicine gels in 1 X Tris-bicine buffer (1 M of Tris/bicine, 10 % SDS) for 
4 hours at 25 mA.  Separated proteins were visualized by staining Coomassie stain (0.1 % 
(w/v) Brilliant Blue G, 25 % (v/v) methanol and 5 % (v/v) acetic acid) (Sigma Aldrich, UK) 
followed by destaining (10 % of acetic acid and 10 % methanol) or transformed to 
nitrocellulose membrane for  subjected to immunoblotting. 
 
                                                              32   
2.13 Western Blotting/ Immunoblotting 
For immunoblotting, separated polypeptides were transferred onto nitrocellulose 
membrane (GE Healthcare). Transferred proteins were visualized by Ponceau S stain for five 
minutes to determine equal loading or the presence of GST fusion proteins. Membranes were 
blocked with  5 % milk in with 1% TBST [(10 %  TBS- 24 g Tris base, 88 g of NaCl, 900 ml 
of distilled water) 9 L of distilled water, 0.1% tween] then incubated with appropriate primary 
antibodies at 4 C overnight (see section 2.3, table 2.1). Membranes washed with three times 
with TBST, exposed to HRP-coupled secondary antibodies for 1 h at room temperature (see 
section 2.3, table 2.2) and further incubated with secondary antibodies (table 2.2) and finally 
washed three times with TBST. Proteins were detected by chemiluminescence ECL (GE 
healthcare) or hypersensitive ECL- Immobilon (Millipore). 
 
2.14 Immunofluorescence Staining (IF) 
For immunofluorescence staining, cells were grown on glass coverslips (0.5x10
5
 cells 
per coverslip), Cells were fixed in 4 % paraformaldehyde for ten minutes at room 
temperature, permeabilised with extraction buffer ((20 mM HEPES pH 7.5, 20 mM NaCl, 5 
mM MgCl2, 1 mM DTT, 0.5% IGEPAL (A-630)) and blocked in 10 % of FCS in PBS for at 
least for one hour at 4 °C. Alternatively for foci analysis, cells were permeabilised with 
extraction buffer for five minutes on ice, then fixed in paraformalaldehyde and blocked as 
above. Coverslips were incubated with primary antibodies for 1 h at room temperature (mouse 
anti-FLAG SET1A and rabbit anti-Rad51; diluted in PBS), followed by three PBS washes and 
incubated with appropriate secondary antibodies (anti-rabbit FITC in 1:500 and anti-mouse 
595 in 1:500) for a further hour in dark at room temperature. Coverslips were washed as 
above, rinsed with distilled water and mounted onto glass slides with Vectashield (Dako) 
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containing 4, 6-diamidino-2-phenylindole (DAPI). Cells were visualized by fluorescence 
microscopy using a Nikon Eclipse E600 (Nikon) with a 60 x or 100 x oil immersion 
objectives in conjunction with a Hamamatsu C474295 camera. Images were captured using 
Velocity software (Perkin Elmer). 
2.15 Bioinformatics analyses 
COSMIC (Catalogue Of Somatic Mutations in Cancer) 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ ) and cbioportal 
(http://www.cbioportal.org/public-portal/ ) databases were interrogated to identify substitution 
mutations in PFAP associated with different types of cancer. The impact of these mutations 
was predicted using Polyphen (http://genetics.bwh.harvard.edu/pph2/) and Mutation Taster 
(www.mutationtaster.org/). Sequence alignments of human PFAP amino acid sequences were 
performed using Clustal W (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
Table 2.3: Accession numbers of sequences used in this study 
Sequences  Accession numbers 
Biorientation of chromosomes in 
cell division protein 1-like 1  
[Homo sapiens] 
NP_683692 
Biorientation of chromosomes in 
cell division 1-like  
[Mus musculus] 
NP_001074891 
Biorientation of chromosomes in 
cell division 1-like  
[Gallus gallus] 
XP_420784 
Biorientation of chromosomes in 
cell division 1-like  
Macacca mulatta 
XP_001098928 
Biorientation of chromosomes in 
cell division 1-like  
Gorilla gorilla 
XP_004038496 
Biorientation of chromosomes in 
cell division 1-like  
Xenopus (Silurana) tropicalis 
XP_002940788 
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3.0 Results 
 
3.1 PFAP interacts with SET1A in vitro  
Previous publications have suggested that PFAP interacts with SET1B, but not with 
SET1A (Nuland et al., 2013). However, data from our laboratory suggests that PFAP and 
SET1A and not SET1B, act together to protect cells from DNA damage (data not shown). 
Therefore, we hypothesize that PFAP (BOD1L) interacts with SET1A histone 
methyltransferase complex. To investigate this hypothesis, we examined whether PFAP 
interacted with SET1A or SET1B by immunoprecipitation (Figure 3.1).  
 
SET1A or SET1B were immunoprecipitated from HeLa nuclear cell extracts using 
specific commercially available antibodies and protein A beads. Protein A beads will bind to 
the immune complexes and pulled down specific antibodies/ antigen complex. As a negative 
control, an IgG immunoprecipitation was included. The resulting immune complexes were 
washed, proteins were separated by SDS-PAGE and analysed by western blotting using 
SET1A, SET1B and PFAP antibodies. In parallel, a fraction of HeLa nuclear cell extract was 
also analysed as input, to show the presence of protein targets that are not immunoprecipitated 
(Figure 3.1). 
 
Endogenous SET1A and SET1B were successfully immunoprecipitated by their 
respective antibodies but not by IgG, and migrated similar distances to SET1A and SET1B as 
visible in the input.  However, cross-reactivities of immunoblotting SET1A and SET1B 
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antibody resulted in the detection of both endogenous SET1A and SET1B proteins in SET1A 
and SET1B immunoblots (Figure 3.1 panel A, B).  
In addition, immunoblotting of PFAP revealed that, whilst PFAP was present in the 
input sample and immune complexes using the SET1A antibody, it was absent from 
immunoprecipitates of SET1B (Figure 3.1 panel C). Reciprocal experiments performed in 
parallel in our laboratory confirmed that immunoprecipitates isolated with a PFAP-specific 
antibody contained SET1A but not SET1B (Figure 3.2). These immunoprecipitation analyses 
establish that PFAP interacts with histone methyltransferase SET1A in vitro but not with 
SET1B. 
 
3.2 Identification of the SET1A binding region of PFAP 
Since our initial experiments strongly suggested that PFAP interaction with SET1A in 
vitro, we therefore, wished to identify the region of PFAP necessary for this interaction. Since 
PFAP is a large protein of over 3000 amino acids, therefore, we first created several 
fragments of PFAP, each encoding roughly 500-600 amino acids, with the aim of using these 
to identify regions of PFAP important for interactions. 
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Figure 3.1: Analyses of in vitro interactions between PFAP and 
SET1A/SET1B by co-immunoprecipitation. HeLa nuclear extracts 
were immunoprecipitated with either anti-SET1A or anti-SET1B 
antibodies. IgG was used as a negative control. Antibody-bound 
proteins were collected with Protein A beads, immune complexes 
washed and separated by SDS-PAGE, and then analyzed by 
Western blotting. Blots were probed with anti-SET1A (panel A), anti-
SET1B (panel B) and anti-PFAP (panel C) antibodies.  
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Figure 3.2: Analysis of in vitro interactions 
between PFAP and SET1A by co-
immunoprecipitation. HeLa nuclear extracts were 
immunoprecipitated with anti-PFAP antibody or 
IgG. Immune complexes were analysed as in 
Figure 3.1 using anti-SET1A or anti-PFAP 
antibodies. Data courtesy of Dr. M. Higgs. 
PFAP 
SET1A 
5% input 
αIgG αPFAP 
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3.2.1 Constructions of GST-tagged PFAP fragments 
As mentioned above, six overlapping of PFAP (previously constructed in our 
laboratory), termed fragments 1-6 (F1-F6) were available (see figure 3.3 for a schematic). 
These fragments also encoded NotI and SalI restriction sites at their termini to aid cloning 
(Figure 3.4). These six fragments were cloned into the pGEX-3X vector, downstream of 
glutathione sepharose transferase (GST) as shown in figure 3.4. To insert these fragments, 
pGEX 3X vector was digested using NotI and SalI (Figure 3.4). This enabled the IPTG-
inducible expression of these fragments as GST-tagged fusion proteins (Figure 3.5). 
 
3.2.2 Small-scale expression of GST-tagged PFAP 
fragments 
To express the fusion proteins described above, the plasmids encoding the PFAP 
fragments, plus an empty (pGEX-3X) vector used as a negative control, were transformed into 
BL21 Escherichia coli. Single colonies of transformed cells were picked and grown into 
starter cultures using Luria broth (LB) media containing ampicillin in the absence (uninduced) 
or in the presence of IPTG. GST-fusion expressions were induced by adding isopropyl-β-D-
thiogalactoside (IPTG). Expression of these GST-fusions were monitored by SDS-PAGE, 
subjected to Brilliant coomassie blue stain and visualized by autoradiography. In parallel, a 
fraction of uninduced culture was used as an uninduced control (Figure 3.6). 
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Figure 3.3: Schematic representation of PFAP and its 
GST-tagged fragments. (Upper panel) The positions of 
the known ATM/ATR phosphorylation sites within PFAP, 
as well as the identifiable domains, are indicated. (Lower 
panel) Approximate positions within PFAP, sizes in aa, 
and molecular masses of the six PFAP fragments. GST 
tags are denoted in red. 
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Figure 3.4: Cloning strategy to produce GST-tagged PFAP 
fragments. PFAP fragments were amplified from human cDNA 
using primers containing SalI or NotI restriction sites (not shown). 
Both the pGEX-3x vector and the amplified PFAP fragment were 
digested using SalI and NotI restriction enzymes, and PFAP 
fragments were ligated into pGEX-3x upstream of glutathione 
sepharose transferase.  
 
PFAP 
fragment 
pGEX-3x 
SalI NotI 
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  PFAP fragment 
pGEX-3x 
+ IPTG 
 PFAP fragment  GST 
Figure 3.5: Strategy for expressing GST-tagged fragments 
of PFAP. Plasmids encoding PFAP fragments, or empty 
vector controls, were transformed into BL21 E. coli (not 
shown). Addition of IPTG to the bacterial growth media 
stimulates transcription from the pGEX-3x promoter, allowing 
the expression of the tagged fragment. 
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Figure 3.6: Small scale expression of GST-tagged fragments of 
PFAP. Plasmids encoding PFAP fragments, or empty vector controls, 
were transformed into BL21 E. coli. Single colonies were picked and 
grown in small ‘starter cultures’ in the absence (uninduced) or presence 
of IPTG. Bacterial pellets were collected 3 hours after induction, lysates 
prepared, and separated by SDS-PAGE. Gels were coomassie stained 
to reveal polypeptides. Induced proteins are denoted with an * and the 
position of molecular weight markers is indicated. 
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SDS-PAGE results shows that  F1, F2, F3, F5, F6 and empty vector (negative control) were 
induced by IPTG as these fragments were expressed at their respective molecular weight, 
indicated by asterisks (Figure 3.6, lanes 3-8) and also shown in figure 3.3. On the other hand, 
uninduced culture was expressed at roughly 48KDa (molecular weight of PGEX 3X vector) 
(Figure 3.6, lane 2).  
 
3.2.3 in vitro protein-protein interaction of the F1 fragment 
of PFAP  
Amino terminus (N-terminal) of PFAP fragment contains sequences (55-164aa) that 
are homologous to BOD1 and yeast Shg1 (Shg1p) proteins. BOD1 (Bi-orientation defected 
1), is a protein important for "chromosome segregation during mitosis" and belongs to the 
same Fam44 protein family as PFAP (Porter et al., 2007). On the other hand, Shg1 protein is 
a part of SET1C COMPASS histone methyltransferase complex in yeast, and is said to be 
functionally analogous to SET1 complex in humans (Nuland et al., 2013). Therefore, these 
sequences at the N-terminal of PFAP are termed as Shg1H domain. Shg1H domain is located 
in F1 fragment (Figure 3.7, upper panel). Thus, in vitro interaction of GST-tagged F1 
fragment and SET1A was investigated, using GST-tagged F2 fragment as a negative control 
in some experiments. 
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3.2.4 Large scale purification of fragments F1 and F2  
Protein purification was carried out to quantify the large amounts of F1 and F2 
fragments to analyse protein interactions by GST pull down assays. Bacterial pellets of 
expressed F1 and F2 fragments were collected and lysates were prepared and passed over 
glutathione beads. Any unbound proteins were washed with excess glutathione and the 
purified proteins were eluted using elution buffer and dialysed. Purified proteins were 
separated by SDS-PAGE and subjected to brilliant coomassie blue stain. GST (empty pGEX 
3X vector) was purified as a negative control. Purified protein fragments F1, F2 and GST 
indicated by asterisk in figure 3. 7. 
 
3.2.5 PFAP F1 but not F2 interacts with SET1A 
To analyse whether fragments F1 or F2 were sufficient to bind to SET1A in vitro, we 
incubated GST alone, GST-F1, GST-F2 with HeLa nuclear cell extracts. Protein complexes 
containing the GST-fusion proteins were then isolated using glutathione sepharose beads and 
the resulting complexes were washed and analysed by SDS-PAGE and western blotting with 
anti-SET1A and anti-SET1B antibodies. 
 
Immunoblotting of GST pull down demonstrated that only SET1A and not SET1B was pulled 
down with F1 fragment of PFAP (Figure 3.8, lower panel). On the other hand, both SET1A 
and SET1B were not pulled down F2 fragment (Figure 3.8, lower panel). 
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Figure 3.7: Purification of GST-F1 and F2 fragments of PFAP.  
 (Upper panel) Schematic showing the position of the Shg1H domain of 
PFAP in relation to fragments F1 and F2. (Lower panel) Bacteria 
containing pGEX-3x, pGST-F1 or pGST-F2 were grown in large scale 
cultures, induced with IPTG, and lysates prepared. GST-tagged proteins 
were isolated from these lysates using Glutathione beads, and the 
bound proteins eluted with excess glutathione. Twenty-five microlitres of 
the purified proteins was analysed by SDS-PAGE and coomassie 
staining to ensure purification of the appropriate GST-tagged polypetide. 
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Figure 3.8: GST pulldown analyses of interactions between PFAP 
fragments and SET1A/SET1B. (Upper panel) Schematic showing the 
position of the Shg1H domain of PFAP in relation to fragments F1 and F2. 
(Lower panel) GST pulldown assays were performed as in the legend to Fig. 
3.8. Protein complexes were analysed by Western blotting in conjunction with 
(A)anti-SET1A or (B) anti-SET1B. The presence of recombinant proteins in 
the isolated complexes was confirmed by coomassie staining (not shown). 
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GST pull down analyses suggests that endogenous SET1A protein interacts with F1 fragment 
and not F2 fragment of PFAP. On the other hand, endogenous SET1B protein is not 
interacting with either of the PFAP fragments. This confirms our hypothesis that only SET1A 
interacts with PFAP, possibly at the predicted Shg1H domain region of F1 fragment.  
 
3.4 Co-localisation of FLAG-SET1A and Rad51 
In response to mitomycin C, many DNA damage proteins such as Rad51, protein 
important for the homologous recombination relocalises within the nucleus to form distinct 
foci, representing sites where DNA repair takes place. These distinct nuclear foci are 
visualized by fluorescence microscopy. Since, it is known that SET1A is involved in the DNA 
repair. Therefore, we decided next to investigate co-localisation of SET1A with RAD51, to 
examine whether SET1A localises to the sites of ICL repair.  
 
HeLa cell line expressing FLAG-tagged SET1A domain can express FLAG-SET1A 
when induced with doxycycline. FLAG-tagged version of SET1A was used instead of normal 
SET1A because the SET1A specific antibodies that we used for immunoblotting do not detect 
SET1A by immunofluorescence.  
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3.4.1 FLAG-tagged SET1A does not co-localise with Rad51 
after MMC in HeLa cells 
To investigate whether FLAG-tagged SET1A and Rad51 co-localised, HeLa cells 
expressing FLAG tagged SET1A were induced with doxycycline or left uninduced 
(doxycycline negative).  Both induced and uninduced cells were either treated with 50 ng/ ml 
of mitomycin C (MMC) after 24 hours or left untreated. Cells were then fixed and stained 
with anti- rabbit Rad51 and anti-mouse FLAG tagged SET1A antibodies. The cells were 
examined by fluorescence microscopy (Nikon E600) (Figure 3.9).  
 
In the absence of doxycycline, we would expect no FLAG-SET1A expression. 
However, FLAG-SET1A was expressed in the absence of doxycycline, in a pan-nuclear 
fashion. On the other hand, Rad51 was expressed, but did not form foci in the absence of 
MMC exposure. In doxycycline positive and MMC negative cells, we observed similar 
results, i.e. expression of both Rad51 and FLAG-SET1A and a very few distinct foci were 
visible. In cells treated with MMC after 24 hours, nuclear speckles were visible for FLAG-
SET1A, and many distinct visible foci were formed by Rad51 (Figure 3.9). Non-specific 
nucleolar signals with Rad51 antibody which are not foci were observed in Rad51 panels in 
doxycycline induced and uninduced cells in the absence of MMC (Figure 3.9).  
 However, no co-localisation observed as both FLAG-SET1A and Rad51 exhibited non-
overlapping sub-nuclear localization, suggesting both proteins were targeted to different 
genomic sites.   
 
To confirm that FLAG-SET1A was expressed in the absence of doxycycline, we 
performed immunoblotting of HeLa FLAG SET1A using SET1A and FLAG antibodies in 
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cultures. In agreement with the immunofluorescence data, endogenous SET1A was weakly 
expressed in both doxycycline induced and uninduced cells, as expected (Figure 3.10).  
However, we also observed expression of the FLAG- tagged version of SET1A in both the 
absence and presence of doxycycline, suggesting the HeLa cells were 'leaky' i.e. that control 
of the exogenous FLAG-SET1A gene by the doxycycline-inducible promoter had somehow 
been lost. Therefore, we decided to use an alternative U2OS cell line expressing FLAG-
SET1A. 
 
3.4.2 FLAG-tagged SET1A does not co-localize with Rad51 
after MMC in U2OS cells 
  
3.4.2a FLAG-tagged expression in U2OS cells with PFA 
only 
Prior to studying the potential co-localisation of SET1A and Rad51, we wanted to 
check that the cells were expressing FLAG-SET1A in a regulated, doxycycline- inducible 
fashion, and that it could be easily detected by IF. Therefore, U2OS cell lines expressing 
FLAG-SET1A under a doxycycline-inducible promoter were fixed with PFA 
(Paraformalaldehyde) only, before permeabilising the cells. This allowed the stabilisation of 
both soluble and insoluble FLAG-SET1A in its native location. Such experiments illustrated 
that FLAG-tagged SET1A was expressed in the nucleus of these cells only when induced with 
doxycycline, and that the FLAG-tagged SET1A does not express in the absence of 
doxycycline (Figure 3.11).    
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Figure 3.9: Immunofluorescence analyses of FLAG-SET1A 
localisation in HeLa cells. HeLa-FLAG-SET1A cells were cultured 
on glass coverslips, and treated with doxycycline or left untreated. 
After 24 h, cells were exposed where indicated to 50 ng/ml MMC 
for 24 h. Cells were pre-extracted, fixed and FLAG-SET1A and 
Rad51 detected by immunofluorescence using the appropriate 
antibodies. Anti-rabbit FITC and anti-mouse Alexa 595 were used 
as secondary antibodies. Nuclei were counter stained with 4,6-
diamidino-2-phenylindole (DAPI) and cells observed using a 
fluorescence microscope (Nikon). 
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+ 
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Figure 3.10: Immunoblot analyses of HeLa-FLAG-SET1A cells.  
HeLa-FLAG-SET1A cells were treated with doxycycline or left untreated 
for 48 h. Whole cell extracts were prepared and analysed by 
immunoblotting using antibodies to SET1A and FLAG. Data courtesy of 
Dr M.Higgs 
FLAG 
SET1A 
HeLa 
FLAG- 
SET1A 
- + Dox 
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Figure 3.11: Immunofluorescence analyses of FLAG-SET1A 
localisation in U2OS cells. U2OS-FLAG-SET1A cells were 
cultured on glass coverslips, and treated with doxycycline or left 
untreated. Cells were fixed, permeabilised, and FLAG-SET1A 
detected by immunofluorescence using the appropriate antibody. 
Anti-mouse Alexa 595 was used as a secondary antibody. 
Images were captured as in Fig. 3.10. Data courtesy of  
Dr. M.Higgs. 
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3.4.1b U2OS cells treated with MMC  
To examine the co-localisation of FLAG-SET1A and Rad51 in these cells, this time 
around cells were permeabilised using extraction buffer prior to fixing with PFA. This 
allowed the removal of soluble proteins from the cells, thus leaving only chromatin-bound 
structures that can be examined by fluorescence microscope.  
Immunostaining of cells were carried out in the absence and presence of doxycycline, 
before and after exposure to MMC for 24 hours or 48 hours (Figure 3.12). Figure 3.12 
indicates that, in the absence of both doxycycline and MMC, FLAG-SET1A was not 
expressed, and Rad51 forms few or no distinct foci. However, in MMC treated U20S cells 
after 24 hours and 48 hours in the absence of doxycycline, Rad51 foci were formed. On the 
other hand, in the presence of doxycycline cells, without MMC treatment, FLAG-SET1A was 
expressed, but formed no distinct foci. In contrast, Rad51 formed few visible foci in the 
presence of doxycycline cells without MMC treatment.  Exposure of doxycycline-treated cells 
to MMC after 24 hours or 48 hours, FLAG-SET1A was expressed but formed no distinct foci, 
whilst Rad51 formed more distinct foci (Figure 3.12). These data confirms that although both 
FLAG-SET1A and Rad51 reveals distinct sub-nuclear localisation (Figure 3.12, merged 
panel), but the formation of Rad51 foci in FLAG-tagged SET1A cells,  in the presence of 
MMC suggests that SET1A is involved in interstrand crosslink repair. 
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Figure 3.12: Immunofluorescence analyses of FLAG-
SET1A localisation in U2OS cells. U2OS-FLAG-SET1A cells 
were cultured and treated as in Fig. 3.11. Twenty-four hours 
post addition of doxycycline, cells were exposed where 
indicated to 50 ng/ml MMC for a further 24 or 48 h. Cells were 
pre-extracted, fixed, and FLAG-SET1A and Rad51 detected by 
immunofluorescence as in Fig. 3.10. 
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3.5 Interaction of PFAP with other fanconi anaemia proteins  
Our preliminary data suggests that PFAP is a component of the Fanconi anaemia 
pathway in particular acting downstream of the mono-ubiquitinated FANCD2-FANCI 
complex (data not shown). Therefore, we decided to examine PFAP interactions with Fanconi 
anaemia proteins such as FANCD2, FANCJ and FANCM.  
 
PFAP was immunoprecipitated from HeLa nuclear extracts and the immune complexes were 
blotted for the presence of PFAP, FANCD2, FANCJ and FANCM. As a positive control, we 
also examined the immunoprecipitates for the presence of SET1A, which we have previously 
demonstrated to interact with PFAP by immunoprecipitation (see section 3.1). PFAP 
immunoprecipitated SET1A as expected (Figure 3.13). Surprisingly, FANCD2 and FANCJ 
was co-immunoprecipitated with PFAP, but was absent from immunoprecipitates from IgG 
(Figure 3.13, top panel and bottom left panel). Two bands were observed in co-
immunoprecipitation of PFAP and FANCJ. The band detected at 140 KDa is the FANCJ band 
(Figure 3.1- bottom left panel). In contrast, FANCM was not detected by anti-FANCM 
antibodies in the input, or in the immunoprecipitates (Figure 3.13, lower right panel).  
 
Although the above data suggests that PFAP interacts with FANCD2 and FANCJ in vitro, 
further work is required to confirm my observations. Unfortunately, time constraints 
precluded me from carrying out this work.   
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<PFAP 
Figure 3.13: Analyses of in vitro interactions between 
PFAP and Fanconi anaemia proteins by co-
immunoprecipitation. HeLa nuclear extracts were 
immunoprecipitated with either anti-PFAP antibodies. IgG was 
used as a negative control. Antibody-bound proteins were 
collected with Protein A beads, immune complexes washed 
and separated by SDS-PAGE, and then analyzed by Western 
blotting. Blots were probed with anti-FANCD2 (panel A), anti-
SET1A (panel B), anti-PFAP (panel C), anti- FANCJ (panel D) 
and anti-FANCM (panel E) antibodies.  
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3.6 Cancer associated mutations might affect interaction of 
PFAP and SET1A 
Since both PFAP and SET1A are involved in maintaining genetic stability, we 
hypothesized that the interaction of SET1A with PFAP may be disrupted by mutations of 
PFAP in tumorigenesis, and that this maybe the cause of genetic instability in these tumours.  
Therefore, we conducted screening of cancer-associated mutations in PFAP using COSMIC 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) (Bamford et al., 2004) and 
cbioportal   (http://www.cbioportal.org/public-portal/) (Gao et al., 2013; Cerami et al., 2012) 
databases. Over two hundred cancer-associated mutations were spread throughout the length 
of PFAP were found in both databases (Figure 3.14) 
 
In particular mutations within the F1 fragment were studied further, as the N-terminal 
region of F1 fragment of PFAP contains shg1H domain that we hypothesize to interact with 
SET1A. There were twenty one mutations found in F1 fragment of PFAP (Figure 3.15). Of 
these twenty one mutations, approximately one third of the mutations were located in the 
Shg1 domain of F1 fragment (Figure 3.16). Most of these were substitution mutations, with 
frameshift mutations at amino acid positions 137 (in the Shg1 domain) 335,   494, and 519 
(rest of the F1 fragment of PFAP) (Figure 3.15-3.16).  
 
 
In order to examine whether the identified mutations were likely to be disease-causing 
or deleterious to the function of PFAP, we used two prediction programs, Polyphen and 
Mutation Taster (Schwarz et al., 2014), to predict the effect of the various amino acid 
substitutions identified in the F1 fragment of PFAP (Table 3.2).  
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Figure 3.14: Schematic representation of cancer-associated 
mutations in PFAP. Mutations in PFAP were identified using the 
COSMIC (Bamford et al., 2004) and CBioportal databases (Gao et 
al. Sci Signal. 2013; Cerami et al. Cancer Discov. 2012). The 
positions and nature of the mutations are indicated: substitution 
missense mutations are in green, and non-sense or frameshift 
deletions are in red. The position of the Shg1H domain is indicated. 
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Figure 3.15: Schematic representation of cancer-associated mutations 
in the F1 fragment of PFAP. Mutations in the F1 fragment of PFAP (aa 1-
600) were identified using the COSMIC database. The positions (in aa) and 
nature of the mutations is indicated, and the different colours denote the 
origin of the tumours in which they were found (lower panel). 
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Figure 3.16: Schematic representation of cancer-associated 
mutations in the Shg1 homology domain of PFAP. Mutations in the 
Shg1H domain of PFAP (aa 55-155) were identified using the COSMIC 
database. The positions (in aa) and nature of the mutations is indicated, 
and the different colours denote the origin of the tumours in which they 
were found (lower panel). 
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Table 3.1:  List of deleterious mutations within the Shg1 domain of PFAP.  (Adapted from 
Adzhubei et al., 2010; Schwarz et al., 2014). 
 
 
Table 3.1 demonstrates that apart from mutation at position 56, the rest of the mutations were 
predicted to be deleterious or harmful mutations that disrupt PFAP function.  
Mutations Cancer Benign or 
deleterious 
mutations in 
Polyphen 
Benign or 
deleterious 
mutations in 
Mutation Taster 
M56V Prostate carcinoma Benign Benign 
G130V Liver hepatocellular 
carcinoma 
Deleterious or 
disease causing 
Deleterious or 
disease causing 
R133Q Ovarian carcinoma Deleterious or 
disease causing 
Deleterious or 
disease causing 
Q137* Ovarian carcinoma Deleterious or 
disease causing 
Deleterious or 
disease causing 
V139M Lung carcinoma Deleterious or 
disease causing 
Deleterious or 
disease causing 
F147I Lung carcinoma Deleterious or 
disease causing 
Deleterious or 
disease causing 
V151L Lung carcinoma Deleterious or 
disease causing 
Deleterious or 
disease causing 
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Protein alignment of the PFAP F1 fragment with other mammals, amphibians, Shg1 protein in 
yeast conducted using ClustalW software (Larkin et al., 2007) , revealed that Shg1H domain 
was conserved in other species (Accession number provided in table 2.3) (Figure 3.17, 3.18). 
This alignment also shows that mutations found in PFAP Shg1H domain were also conserved 
in homologous proteins of other species. This suggests that these mutations are more likely to 
disrupt the function of PFAP and may also have an effect on PFAP and SET1A in vitro 
interaction.  
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Figure 3.17: The position of cancer-associated mutations within the 
Shg1H domain of PFAP relative to amino acids conserved amongst 
mammalian/amphibian PFAP sequences. Amino acid sequences of PFAP 
sequences were obtained from the Refseq database and aligned using 
ClustalW (Larkin et al., 2007). Absolutely conserved amino acids are 
marked with a *. Positions of cancer-associated mutations are indicated with 
red arrows. 
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Figure 3.18: The position of cancer-associated mutations within the 
Shg1H domain of PFAP relative to amino acids conserved amongst 
mammalian/amphibian PFAP sequences. Amino acid sequences of PFAP 
sequences were obtained from the Refseq database and aligned using 
ClustalW. Absolutely conserved amino acids are marked with a *. Positions 
of cancer-associated mutations are indicated with red arrows. 
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4.0 Discussion 
 
4.1 PFAP interacts with SET1A in vitro 
PFAP (Putative Fanconi Anaemia Protein) is a large nuclear protein of unknown 
function, which belongs to the Fam44 family of proteins. Despite its size (3051aa), PFAP 
consists of few identifiable domains, which includes an N-terminal domain with homology to 
the COMPASS/HMT yeast component Shg1 (Shg1H domain), A-T hook and several 
identified ATM/ATR phosphorylation sites (Figure 1.5). Recent study carried out by van 
Nuland and co-workers (2013) have suggested that PFAP interacts with SET1B (Nuland et 
al., 2013). However, unpublished data from our laboratory suggests that PFAP interacts with 
SET1A (Figure 3.2), the catalytic subunit of another histone methyltransferase. Thus, we 
hypothesised that PFAP interacts with SET1A rather than with SET1B as suggested by van 
Nuland et al (2013).  
Immunoprecipitation of endogenous SET1A and SET1B with PFAP antibodies 
demonstrated that PFAP was pulled down with endogenous SET1A but not with SET1B 
(Figure 3.1). This suggests that PFAP strongly interacts with SET1A, but not with SET1B.   
 
Our initial studies have shown that PFAP strongly interacts with SET1A and not with SET1B. 
However, cross-reactivities between immunoblotting SET1A and SET1B antibodies and 
immunoprecipitating anti-SET1B and anti-SET1A antibodies respectively (Figure 3.1- left 
and centre panels)  suggesting that antibodies needs to be specific to detect specific protein of 
interests, otherwise it can lead to false negative results. For example, cross-reactivity can be 
interpreted as SET1A and SET1B interacting with each other, therefore, SET1B would be 
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accepted to be interacting with PFAP, which the results from our study does not show. 
Therefore, to prove this, specific antibodies are required to prevent the cross-reactivity.  
 
PFAP was shown to be associated with BOD1 protein in the van Nuland study. The 
authors therefore, conclude that since BOD1 and SET1B interacts, PFAP is a part of SET1B 
histone methyltransferase complex. However, our data contradicts this claim. The other 
possible reason for this discrepancy could be that PFAP was also being pulled down with 
other non-catalytic subunits including WDR5, RBBP5, ASH2L and DPY30  which are shared 
by all SET/COMPASS complexes and Cfp1 and Wdr82 are shared by only SET1A/SET1B 
complexes (Figure 1.6) (van Nuland et al., 2013).  
 
Since initial experiments strongly suggested that PFAP interacts with SET1A and not with 
SET1B, we therefore wished to identify the regions of PFAP responsible for binding to 
SET1A. To be able to answer this question, and since PFAP is a very large protein, six 
overlapping fragments of approximately 500-600 amino acids in length were generated. These 
fragments were introduced into pGEX 3X vector upstream of GST, to form GST-tagged 
pGEX encoded PFAP fragments, and bacterially expressed upon addition of IPTG. Once 
induced, only the GST-tagged F1 and F2 fragments were purified for further analyses of 
interactions of SET1A with PFAP.  
 
Only the F1 fragment and F2 fragment were used to analyse interactions of PFAP with 
SET1A/SET1B. We chose these fragments as N-terminal region of PFAP contains sequences 
known as Shg1H domain similar to BOD1 and Shg1 protein. Therefore, we hypothesise that 
this so-called Shg1H domain of PFAP may contain sequences that interact with SET1A. The 
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Shg1H domain is located in the F1 fragment and is positioned between amino acids 55- 164.  
However, it does not mean that SET1A only interacts with F1 fragments; the other GST-
tagged fragments of PFAP not analysed here may also bind SET1A.  
The interaction between the GST-tagged PFAP fragments and SET1A was examined 
using GST pull down assays, using GST as negative control. GST pull down analysis 
demonstrated that endogenous SET1A was pulled down with F1 but not F2, whereas, SET1B 
was not pulled down by either of the fragments (Figure 3.8). These analyses further confirm 
that SET1A interacts with PFAP, particularly with F1 fragment of PFAP possibly at the Shg1 
domain. Although, we hypothesise that the interaction occurs within the Shg1H domain, this 
needs to be proved experimentally by specifically examining the interaction of Shg1H domain 
of PFAP with SET1A to confirm our hypothesis. 
 
One question which arises from our initial studies is whether the interaction between 
PFAP and SET1A is direct or is it mediated via another component of SET1A complex? It 
has been shown that SET1A and SET1B HMT complex share many conserved subunits such 
as Wdr5, Rbbp5, ASH2L, Wdr82, DPY30, Cfp1 (Figure 1.6) (Nuland et al., 2013).  If the 
interaction of SET1A and PFAP was indirect (i.e. via other members of both HMT 
complexes) or  mediated via  BOD1 protein then we would have likely observed a strong 
interaction of PFAP with both SET1A and  SET1B. Therefore, it is so likely that PFAP and 
SET1A interacts directly or there are other unidentified components.   
The above data leads us to speculate as to the role of PFAP in histone methylation. 
From our data, we hypothesise that PFAP is involved in the ICL repair pathway. However, 
the mechanism(s) behind its role in this repair pathway are still unknown. Therefore, we can 
only speculate that PFAP is involved in the regulation of histone methylation based on the 
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results from the above experiments and from unpublished previous studies from our 
laboratory.  
 
So far the function of PFAP is unknown. However, recent independent studies have 
raised a possibility of the role of PFAP in histone methylation.  Eberl et al (2013) has shown 
that PFAP act as a "significant interactor" for K4me3 chromatin marks for the activation of 
lysine methylation on histone three (Eberl et al., 2013). Secondly, Nuland and co (2013) have 
demonstrated that PFAP interacts with SET/COMPASS like histone methyltransferase 
complexes - SET1A, SET1B, which are involved in the regulation of global levels of lysine 
methylation. On the other hand, Dehe and co (2006), showed that Shg1 protein (region of the 
yeast SET1C complex similar to Shg1H domain of PFAP)  inhibits the level of di- and tri-
methylation on H3K4, indirectly suggesting that PFAP may inhibit di-methylation and tri-
methylation of lysine, (Dehe et al., 2006). Therefore, it becomes essential to investigate the 
role of PFAP in histone methylation and identify other interactors from the SET1A complex 
apart from endogenous SET1A protein.  
 
Alternatively, the role of PFAP in methylation could also be investigated by several 
methods.  Firstly, enzymatic activity of purified GST-tagged fragments of PFAP mainly F1 
and F2 could be analysed by immunoblotting against anti-histone H3, methylated lysines. 
Secondly, we could possibly identify which GST-tagged PFAP fragment(s) interacts with 
histones using histone pull down assays, wherein GST-fusion proteins of PFAP fragments are 
incubated with recombinant or native histone octamer, precipitated using GST beads and 
analyse by SDS-PAGE. This will hopefully show that native histones are pulled down with 
GST-tagged PFAP fragments, and further analyse for histone lysine methylation marks by 
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immunoblotting. Or simply we can just measure the level of histone methylation in PFAP cell 
lines. These techniques could assist in elucidating the role of PFAP in histone methylation.  
 
4.2 PFAP interaction with other Fanconi anaemia proteins 
PFAP is believed to be involved in the fanconi anaemia pathway, in particular 
downstream of FANCI-FANCD2. Therefore, we wished to examine the interaction of PFAP 
with other Fanconi anaemia proteins. We chose to analyse interactions FANCD2, FANCJ and 
FANCM, as we had antibodies readily available for these proteins. Co-immunoprecipitation 
analyses demonstrated that FANCD2 and FANCJ interacted with PFAP, as both FANCD2 
and FANCJ were pulled down by PFAP (Figure 3.13). However, immunoprecipitation of 
PFAP with FANCJ resulted in the detection of two bands. Out of these two bands, lower band 
expresses FANCJ protein. However, this need to be confirmed by running mutant FA-J cell 
line in parallel, as a negative control (Figure 3.13- bottom left panel).    
 
These interactions were not surprising as FANCD2 (mono-ubiquitinated form of 
FANCD2) relocalises to the chromatin where it binds to BRCA2 and thus, facilitates the 
trigger of homologous recombination repair, which FANCJ is also believed to be part of. 
Further investigation of the interaction between FANCD2, FANCJ and PFAP must be carried 
out to confirm these findings and to ascertain the functions of this interaction. Future 
investigations should include reciprocal immunoprecipitation of FANCD2/ FANCJ to pull 
down PFAP, followed by co-localisation of FANCD2, FANCJ and PFAP.  
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4.3 FLAG-SET1A and Rad51 exhibits distinct sub-nuclear 
localization 
In addition to examining the in vitro interaction of PFAP and SET1A, we decided to 
investigate co-localisation of FLAG-SET1A and RAD51, to see whether SET1A localises to 
ICL repair sites along with Rad51, which relocalises to nucleus to form distinct foci in 
response to MMC. Co-localisation was studied in HeLa cells and U2OS cells 
immunofluorescence staining. FLAG-tagged version of SET1A was used as antibodies for 
endogenous SET1A did not work properly.  Immunofluorescence staining of both HeLa cells 
and U20S cells expressing FLAG-tagged version of SET1A demonstrated that Rad51 formed 
distinct foci in the presence of MMC in both cell lines (Figure 3.12), but no distinct foci were 
formed for FLAG-tagged SET1A in U20S cells (Figure 3.12), instead formed speckles in 
HeLa cells in doxycycline positive cells in the presence of MMC (Figure 3.10). Nevertheless, 
no co-localization was found as both FLAG-SET1A and Rad51 exhibit non-overlapping sub-
nuclear localisation. The formation of many Rad51 foci in FLAG-tagged SET1A in 
doxcycline induced  U2OS and HeLa cells after 24 and 48 hours of MMC treatment (Figure 
3.9 and 3.12)  indicates that SET1A is involved in ICL repair although, both SET1A and 
Rad51 proteins have distinct functions in ICL repair pathway.  
 
The limitations of studying co-localisation using fluorescence microscope are 
bleaching and dealing with fixed or dead cells. Bleaching could result in loss of signals or 
activity. Therefore, bleaching can be prevented by reducing the length of the exposure or 
using more robust fluorophores that are less prone to bleaching. The other limitation is that 
immunofluorescence staining is always carried out in fixed or dead cells. Using fixed cells 
result in cross-linking of SET1A and Rad51, thus, resulting in false positive or false negative 
signals as a result of specific binding. These problems can be overcome by using alternative 
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approaches such as green fluorescent protein (GFP), which allow studying localization of 
proteins in living cells.  
Alternative to fluorescence microscopy is to use confocal microscopy. Confocal microscopy 
provides better resolution, 3D visualisation and eliminates out-of-focus objects.  
4.4 Cancer-associated mutations disrupts interaction of 
PFAP and SET1A in vitro  
As both PFAP and SET1A are involved in the maintenance of genomic stability (our 
unpublished data), we, therefore, hypothesised that the interaction of SET1A with PFAP may 
be disrupted by mutation of PFAP in tumorigenesis, and that this maybe the cause of genetic 
instability in these tumours. Screening of COSMIC and cbioportal database identified over 
two hundred mutations; one third of these mutations were found in Shg1H domain of PFAP 
(Figure 3.16) and amino acids responsible for mutations in Shg1H domain were conserved in 
other mammalian and amphibian species (Figure 3.17). This suggests that these mutations 
may disrupt the in vitro interaction of PFAP and SET1A. As the crystal structure of PFAP has 
not been resolved, we cannot confirm that these mutations will have an impact on interaction 
of PFAP and SET1A using in silico analyses. However, we could confirm this by introducing 
these Shg1 mutations into GST-tagged F1 fragment of PFAP using site-directed mutagenesis 
and study the interaction between these mutant PFAP fragments and SET1A by the same 
techniques used in this study. Hopefully, this would show whether mutations has any effect 
on the in vitro interactions of SET1A and PFAP. These mutations might have an slight or 
drastic effect on the levels of histone methylation, but we don't know. These mutations may 
also affect the interactions of FANCD2 and PFAP, provided they both interact at Shg1H 
domain.  
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4.5 Future work 
In future, if I am provided with an opportunity to continue with this project, firstly I would 
confirm that predicted Shg1H domain of the GST-tagged F1 PFAP fragment  is the region 
where interaction between PFAP and SET1A. This would be done by generating GST-
tagged Shg1H domain fragment by expressing in the same pGEX 3X vector, inducing 
protein expression, purifying and thus studying its in vitro interaction with PFAP using 
GST pull down assays, wherein GST-Shg1H domain would be used as a bait protein and 
SET1A as a prey protein. 
 
The other way of confirming in vitro interactions between PFAP and SET1A is through co-
localisation studies by immunofluorescence staining. Since, it is known that PFAP and 
SET1A interacts in vitro, therefore, it would be interesting know whether both the proteins  
which interacts in vitro, behaves in the same way in a cancer cell line treated with MMC or 
left untreated. When the cells are exposed to MMC, hopefully distinct foci becomes visible 
for both SET1A and PFAP, which suggests that both set of proteins are involved in ICL 
repair. On the other hand, if the foci of both proteins are observed at the same place, this will 
also demonstrate that both SET1A and PFAP are co-localised at the ICL repair sites. 
 
Secondly, mutations found in Shg1H domain could disrupt the interaction between SET1A 
and PFAP. This can be confirmed by inserting these mutants into Shg1H domain by site-
directed mutagenesis. In site directed mutagenesis, Primers designed will contain desired 
mutations and will be complementary to the template DNA around the mutation site, so it can 
hybridise with the DNA in the gene of interests. The single strand primer is extended using a 
DNA polymerase, which copies the rest of the gene. This mutant Shg1H gene is introduced 
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into sub-cloning vector and cloned. And then we would be able to express, purify and 
detected this mutants as GST-fusion products as before and study its interactions with SET1A 
by doing GST-pull down assays.  
 
4.6 Summary 
Interstrand crosslinks are highly toxic lesions caused by DNA crosslinking agents 
such as Mitomycin C.   These interstrand crosslinks are repaired by the Fanconi anaemia 
pathway. PFAP (Putative fanconi anaemia protein) is a novel protein uncharacterised protein, 
which we propose it to be involved in Fanconi anaemia pathway, acting downstream of 
mono-ubiquitinated FANCI- FANCD2 (I-D2 complex). However, its role in this pathway still 
remains elusive. Van Nuland and co-worker showed that PFAP interacts with 
SET/COMPASS like histone methyltransferase called SET1B. However, unpublished data 
from our laboratory demonstrates that PFAP interacts with SET1A (another histone 
methyltransferase belonging to the same SET/COMPASS group) rather than SET1B. 
Therefore, we hypothesized that SET1A interacts with PFAP in vitro.   
 
Firstly, in this study, we have demonstrated that the PFAP interacts with catalytic 
subunit of SET1A HMT called SET1A. This interaction is predicted to takes place at Shg1H 
domain in F1 fragment of PFAP. We have also speculated that any substitution mutations in 
Shg1 domain of F1 fragment of PFAP could disrupt the interaction of PFAP and SET1A.  
 
Secondly, as SET1A is involved in DNA repair, therefore we wished to study whether 
SET1A localises to sites of ICL repair, as a result co-localisation of FLAG-tagged SET1A 
(SET1A) with Rad51 was studied. We did not find any co-localization, as both revealed non-
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overlapping sub-nuclear localisation, suggesting that both proteins targets specific genomic 
sites and therefore, SET1A does not localise to the sites of ICL repair. However, with the 
formation of distinct foci in Rad51 panel when treated with MMC, illustrates that SET1A is 
involved in ICL repair.   
 
Ultimately, in vitro interaction of PFAP and other fanconi anaemia proteins including 
FANCD2, FANCJ and FANCM were study as PFAP is believed to be involved in Fanconi 
anaemia pathway, in particular downstream of mono-ubiquitination of FANCI- FANCD2. 
Immunoprecipitation analyses demonstrated that FANCD2 and FANCJ interacts with PFAP, 
however, further investigations are required to confirm this findings.   
 
To conclude, PFAP is a large nuclear protein with unknown function. However, two 
independent studies had raised the possibility that PFAP may play role in the regulating 
histone methylation, via interactions with the methylated forms of Lys4 of histone H3 (Eberl, 
2013), and through a possible interaction with SET/COMPASS like histone 
methyltransferases SET1A/SET1B (Nuland et al., 2013). In this study, we have been 
successful in demonstrating in two key points: 
 
 Firstly, that PFAP interacts with SET1A and not with SET1B as shown by van Nuland 
(2013), possibly in the Shg1H domain in F1 fragment of PFAP.   
Secondly, in vitro protein-protein interaction of PFAP with FANCD2 and FANCJ confirms 
that PFAP is involved in FA pathway, downstream of FANCD2-FANCI complex.  
                                                              75   
5.0 References 
 
Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., 
Kondrashov, A.S. and Sunyaev, SR. 
 
Akkari, Y. M., Bateman R.L, Reifsteck, C.A., Olson, S.B. and Grompe, M. (2000).  DNA 
replication is required to elicit cellular response to psoralen- induced DNA interstrand cross-
links. Molecular Cell Biology 20(21), 8283- 8290. 
 
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., 
Teague, J., Futreal, PA., Stratton, M.R. and Wooster, R. (2004). The COSMIC (Catalogue of 
Somatic Mutations in cancer) database and website. British Journal of Cancer 91(2), 355- 
358. 
 
Bannister, A.J. and Kouzarides, T. (2005). Reversing histone methylation. Nature 436(7054), 
1103- 1106. 
 
Bernstein, C., Prasad, A.R., Nfonsam, V. and Bernstein, H. (2013). DNA Damage, DNA 
Repair and Cancer, New Research Directions in DNA Repair, Prof. Clark Chen (Ed.), ISBN: 
978-953-51-1114-6, InTech, DOI: 10.5772/53919. Available from: 
http://www.intechopen.com/books/new-research-directions-in-dna-repair/dna-damage-dna-
repair-and-cancer. 
 
                                                              76   
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., 
Byrne, C.J., Heuer, M.L., Larsson, E., Antipin, Y., Reva, B., Goldberg, A.P., Sander, C. and 
Schultz, N. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring 
Multidimensional Cancer Genomics Data. Cancer Discovery 2, 401- 404.  
 
Chapman, J.R., Taylor, M.R. and Boulton, S.J. (2012).  Playing the end game: DNA double-
strand break repair pathway choice. Molecular Cell  47(4),  497-510. 
 
Ciccia, A., Ling, C., Coulthard, R., Yan, Z., Xue, Y., Meetei, A.R., Laghmani, el.H., Joenje, 
H., McDonald, N., de Winter, J.P., Wang, W. and West, S.C. (2007). Identification of 
FAAP24, a Fanconi anaemia core complex protein that interacts with FANCM. Molecular 
Cell 25(3), 331-343.  
 
Ciccia, A., McDonald, N. and West, S.C. (2008). Structural and functional relationships of the 
XPF/MUS81 family of proteins. Annual Reviews of Biochemistry 77, 259- 287. 
 
Ciccia, A. and Elledge, S.J. (2010). The DNA Damage Response: Making it safe to play with 
knives. Molecular Cell 40(2), 179-204. 
 
Cole, R.S. (1973). Repair of interstrand cross-links in DNA induced by psoralen plus light. 
The Yale Journal of biology and medicine 46(5),  492.  
 
Dehe, P.M., Dichtl, B., Schaft, D., Roguev, A., Pamblanco, M., Lebrun, R., Rodriguez-Gil, 
A., Mkandawire, M., Landsberg, K., Shevchenko, A., Shevchenko, A., Rosaleny, L.E., 
                                                              77   
Tordera, V., Chavez, S., Stewart, A.F. and Geli, V. (2006). Protein Interactions within the 
Set1 Complex and Their Roles in the Regulation of Histone 3 Lysine 4 Methylation. The 
Journal Of Biological Chemistry 281(46), 35404 - 35412. 
 
de Winter, J.P. and Joenje, H. (2008).The genetic and molecular basis of Fanconi anaemia. 
Mutation Research 668(1-2), 11-9. 
 
Dillon, S.C., Zhang, X., Trievel, R.C. and Cheng, X. (2005). The SET-domain protein 
superfamily: protein lysine methyltransferases. Genome Biology 6(8), 227-239. 
 
Eberl, H.C., Spruijt, C.G., Kelstrup, C.D., Vermeulen, M. and Mann, M. (2013). A map of 
General and specialized chromatin readers in Mouse tissues generated by label-free 
interaction proteomics. Molecular Cell  49(2),  368-  378. 
 
Fanconi, G. 1927 Familiaere infantile perniziosaartige Anaemie (pernizioeses Blutbild und 
Konstitution). Jahrbuch Kinderheild 117, 257–280 
 
Gao, J., Aksoy, B.A., Dorgrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, 
A., Sinha, R., Larsson, E., Cerami, E., Sander, C. and Schultz, N. (2013). Integrative Analysis 
of Complex Cancer Genomics and Clinical Profiles Using the cBioportal. Science 6(269), 1-
19.  
 
                                                              78   
Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M.S., Timmers, C., Hejna, J., Grompe, 
M. and D'Andrea, A.D. (2001). Interaction of the Fanconi anaemia proteins and BRCA1 in a 
common pathway. Molecular Cell 7(2), 249- 262. 
 
Hoeijmakers, J.H.J. (2001). Genome maintenance mechanisms for preventing cancer. Nature 
411(6835), 366-374. 
 
Howlett, N.G., Harney, J.A., Rego, M.A., Kolling, F.W., 4th and Glover, T.W. (2009). 
Functional interaction between the Fanconi Anaemia D2 protein and proliferating cell nuclear 
antigen (PCNA) via a conserved putative PCNA interaction motif. The Journal of Biological 
Chemistry 284(42), 28935- 28942. 
 
Huang, Y. and Li, L. (2013). DNA crosslinking damage and cancer- a tale of friend and foe. 
Translational Cancer Research 2(3), 144-154. 
 
Ishiai, M., Kitao, H., Smogorzewska, A., Tomida, J., Kinomura, A., Uchida, E., Saberi, A., 
Kinoshita, E., Kinoshita-Kikuta, E., Koike, T., Tashiro, S., Elledge, S.J. and Takata, M. 
(2008).  FANCI phosphorylation functions as a molecular switch to turn on the Fanconi 
anaemia pathway. Nature Structural & Molecular Biology 15(11), 1138- 1146. 
 
Jackson, S.P. and Bartek, J. (2009). The DNA-damage response in human biology and 
disease. Nature  461(7267), 1071- 1078. 
 
                                                              79   
Jenuwein, T. and Allis, C.D.  (2001). Translating the histone code. Science 293(5532),  1074-
1080. 
 
Jorgensen, S., Schotta, G. and Sorensen, C.S. (2013). Histone H4 Lysine 20 methylation: key 
player in epigenetic regulation of genomic integrity. Oxford Journals, 1-10. 
 
Knipscheer, P., Räschle, M., Smogorzewska, A., Enoiu, M., Ho, T.V., Schärer, O.D., Elledge, 
S.J. and Walter, J.C. (2009). The Fanconi anaemia pathway promotes replication-dependent 
DNA interstrand crosslink repair. Science 326(5960), 1698- 1701. 
 
Kottemann, M.C. and Smogorzewska, A. (2013).  Fanconi anaemia and the repair of Watson 
and Crick DNA crosslinks. Nature Reviews 493(7432), 356- 363. 
 
Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H., 
Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., Thompson, J.D., Gibson, T.J. and Higgins, 
D.G. (2007). Clustal W and Clustal X version 2.0. Bioinformatics 23(21), 2947- 2948. 
 
Lee, J.H. and Skalnik, D.G. CpG-binding Protein (CXXC Finger Protein 1) Is a Component 
of the Mammalian Set1 Histone H3-Lys
4
 Methyltransferase Complex, the Analogue of the 
Yeast Set1/COMPASS Complex. (2005). The Journal Of Biological Chemistry 280(50),  
41725-41731. 
 
                                                              80   
Lee, J.H., Tate, C.M., You, J.S. and Skalnik, D.G. Identification and Characterization of the 
Human Set1B Histone H3-Lys
4 
Methyltransferase Complex. (2007). The Journal Of 
Biological Chemistry 282(18),  13419-13428. 
 
Lee, J.E., Wang, C., Xu, S., Cho, Y.W., Wang, L., Feng, X., Baldridge, A. Sartorelli, V., 
Zhuang, L., Peng, W. and Ge, K. (2013). H3K4 mono- and di- methyltransferase MLL4 is 
required for enhancer activation during cell proliferation. eLife  2, 1-39.  
 
Lindahl, T. and Wood, R.D. (1999) Quality control by DNA repair. Science  286(5446), 
1897-18905. 
 
Martin, C. and Zhang, Y. (2005).  The diverse functions of histone lysine methylation. Nature 
Reviews Molecular Cell Biology  6(11),  838-849. 
 
Martin, S.A., Lord, C.J. and Ashworth, A. (2008). DNA repair deficiency as a therapeutic 
target in cancer. Current Opinion in Genetics & Development 18(1), 80-86.  
 
Matsuoka, S., Ballif, B.A., Smogorzewska, A., McDonald, E.R. 3rd, Hurov, K.E., Luo, J., 
Bakalarski, C.E., Zhao, Z., Solimini, Z., Lerenthal, Y., Shiloh, Y., Gygi, S.P. and Elledge, S.J. 
(2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to 
DNA damage. Science 316(5828), 1160-1166 
 
McKinnon, P.J. (2009). DNA repair deficiency and neurological disease. Nature Review 
Neuroscience 10(2), 100-112. 
                                                              81   
 
Miller, T., Krogan, N.J., Dover, J., Erdjument-Bromage, H., Tempst, P., Johnston, M., 
Greenblatt, J.F., Shilatifard, A. (2001).  COMPASS: a complex of proteins associated with a 
trithorax-related SET domain protein. Proceedings of the National Academy of Sciences of the 
United States of America  98(23), 12902-12907. 
 
Moldovan, G.L. and D'Andrea, A.D. (2009). How the Fanconi Anaemia pathway guards the 
genome. Annual Review of Genetics 43,  223- 249. 
 
Moldovan, G.L. and D'Andrea, A.D. (2012). To the rescue: The Fanconi Anaemia genome 
stability pathway salvages replication forks. Cancer Cell 22(1), 5-6.  
 
Morrison, C., Shinohara, A., Sonoda, E., Yamaquchi-Iwai, Y., Takata, M., Weichselbaum, 
R.R. and Takeda, S. (1999). The essential functions of human Rad51 are independent of ATP 
hydrolysis. Molecular Cell Biology 19(10),  6891- 6897. 
 
Niedernhofer, L.J., Lalai, A.S. and Hoeijmakers, J.H.J. (2005). Fanconi anaemia (cross)linked 
to DNA repair. Cell 123(7), 1191-1198. 
 
Niedzwiedz, W., Mosedale, G., Johnson, M., Ong, C.Y., Pace, P. and Patel, K.J. (2004). The 
Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA 
repair. Molecular Cell 15(4), 607-620. 
 
                                                              82   
Nuland, R.V., Smits, A.H., Pallaki, P., Jansen, P.W., Vermeulen, M. and  Timmers, H.T. 
(2013). Quantitative dissection and stoichiometry determination of the human SET1/MLL 
histone methyltransferase complexes. Molecular and Cellular Biology  33(10), 2067-2077. 
 
Patel, K.J. and Joenje, H. (2007). Fanconi anaemia and DNA replication repair. DNA Repair 
6(7), 885-890.  
 
Pecorino, L. (2012).  Molecular Biology of Cancer. 3rd ed. Oxford University Press, Oxford, 
UK. 
 
Porter, I.M., McClelland, S.E., Khoudoli, G.A., Hunter, C.J., Andersen, J.S., McAinsh, A.D., 
Blow, J.J. and Swedlow, J.R. (2007). Bod1, a novel kinetochore protein required for 
chromosome biorientation. The Journal Of Cell Biology 179(2), 187-197. 
 
 
Schlacher, K., Wu, H. and Jasin, M. (2012). A Distinct Replication Fork Protection Pathway 
Connects Fanconi Anaemia Tumour Suppressors to RAD51-BRCA1/2. Cancer Cell 22(1), 
106- 116. 
 
Schwarz, J.M., Cooper, D.N., Schuelke, M. and Seelow, D. (2014). MutationTaster2: 
mutation prediction for the deep-sequencing age. Nat Methods 11(4), 361- 362. 
 
Smogorzewska, A., Matsuoka, S., Vinciguerra, P., McDonald, E.R., 3rd, Hurov, K.E., Luo, J., 
Ballif, B.A., Gygi, S.P., Hofmann, K., D'Andrea, A.D. and Elledge, S.J. (2007). Identification 
                                                              83   
of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. 
(2007). Cell 129(2), 289- 301. 
 
Spycher, C., Miller, E.S., Townsend, K., Pavic, L., Morrice, N.A., Janscak, P., Stewart, G.S. 
and Stucki, M. (2008). Constitutive phosphorylation of MDC1 physically links the MRE-11-
RAD50-NBS1 complex to damaged chromatin. The Journal Of Cell Biology 181(2), 227-240. 
 
Sulli, G., Di Micco, R. and d'Adda di Fagagna, F. (2012). Crosstalk between chromatin state 
and DNA damage response in cellular senescence and cancer. Nature Reviews Cancer 12(10), 
709- 720.  
 
Taniguchi, T., Garcia-Higuera, I., Andreassen, P.R., Gregory, R.C., Grompe, M. And 
D'Andrea, A. (2002). S-phase- specific interaction of the Fanconi anaemia protein, FANCD2, 
with BRCA1 and RAD51. Blood 100(7),  2414 - 2420.  
 
Takata, M., Sasaki, M.S., Sonoda, E., Morrison, C., Hashimoto, M., Utsumi, H., Yamaquchi-
Iwai, Y., Shinohara, A. and Takeda, S. (1998). Homologous recombination and non-
homologous end-joining pathways of DNA double-strand break repair have overlapping roles 
in the maintenance of chromosomal integrity in vertebrate cells. The EMBO Journal 17(18), 
5497- 5508. 
 
Tate, C.M., Lee, J.H. and Skalnik, D.G. (2010).  CXXC Finger Protein 1 Restricts the Setd1A 
Histone H3-Lys4 Methyltransferase Complex to Euchromatin. The FEBS Journal  277(1),  
210- 223. 
                                                              84   
Tischkowitz, M.D. and Hodgson, S.V. (2003). Fanconi anaemia. Journal of Medical Genetics 
40(1), 1-10. 
 
Walden, H.and Deans, A.J. (2014).  The Fanconi anaemia DNA repair pathway: structural and 
functional insights into a complex disorder. Annual Review of Biophysics 43, 257- 278. 
 
Ward, T.A., Dudasova, Z., Sarkar, S., Bhide, M.R., Vlasakova, D., Chovanec, M. and 
McHugh, P.J. (2012). Components of a Fanconi-Like Pathway Control Pso2-Independent 
DNA interstrand Crosslink Repair in Yeast. PLoS Genetics 8(8),  1-14. 
 
Wang, X., Andreassen PR and D'Andrea A.D. (2004). Functional interaction of mono-
ubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Molecular Cell Biology 24(13), 
5850- 5862. 
 
Williams, H.L., Gottesman, M.E. and Gautier, J.  (2012). Replication-independent repair of 
DNA interstrand crosslinks. Molecular Cell  47(1), 140- 147.  
 
Zhang, Y. and Reinberg, D. (2001). Transcription regulation by histone methylation: interplay 
between different covalent modifications of the core histone tails. Genes & Development 
15(18), 2343- 2360.  
 
 
 
 
                                                              85   
 
